However, the percentage of piglets weighing less than 1000 g in the treatment 2 group (11.1%) showed a trend towards being lower compared to the control (15.0%, p = 0.111) and treatment 1 (15.2%, p = 0.063) groups ( Table 1 ).
Although perception in the vaccine’s ability to prevent complications showed a trend toward higher uptake (24.0% vs 13.0%), the association was not statistically significant ( P = .112).
The cohort was grouped based on BRAF V600E mutation status and group to group analysis showed a trend toward higher prevalence among male patients to harbor the mutation (63.3% vs. 42%; P = 0.112), [ Table 1 ].
p53 and PCDH17 were each significantly associated with survival from bladder cancer (p=0.038, p=0.031, p=0.031, Figure 2 A, 2B, 2C), while low-expression of Beclin-1 just showed a trend towards patient survival (p=0.112, Figure 2 D).
Mortality showed a trend toward higher odds with stent-assisted coiling (OR 3.29, 95% CI: 0.76–14.32; p = 0.113), although this did not reach statistical significance.
Kaplan–Meier analysis showed a trend toward improved survival (HR = 0.89; log-rank P = 0.113) ( Fig. 3a ).
AHSS total scores showed a trend toward improvement in the java water-dropwort extract group (10.879 ± 10.222) compared to the placebo group (21.333 ± 20.938, p = 0.113), although this was not statistically significant.
Higher B2M concentration showed a trend toward increased frailty prevalence (PR of 4.83, 95% CI 0.69–33.81, p = 0.113).
Results Total nucleosome levels measured by ELISA showed a trend to lower levels in plasma of CRC patients as compared with non-malignant controls ( Table S1 ) (medians 0.39 vs. 0.67; p = 0.113).
Dose–response analysis further showed ( Table 3 , Figure 5a ): nadolol and propranolol showed a non-significant trend of risk reduction with increasing dose (nadolol: β = −0.00783, p = 0.422, R 2 = 0.133; propranolol: β = −0.00363, p = 0.397, R 2 = 0.104); Atenolol showed a trend of risk increase with increasing dose ( β = 0.01530, p = 0.113, R 2 = 0.622), though not statistically significant; metoprolol had no obvious dose–effect relationship ( β = −0.00049, p = 0.892, R 2 = 0.005).
The apparent volume of distribution (Vz/F) showed a trend toward an increase (58% increase, p = 0.113) in the HAE group. 3.
Although KRAS mutation–positive patients showed a trend toward a shorter survival compared with those negative for KRAS and EGFR mutations as well as for fusion genes (9.99 vs. 12.9 months, P = 0.113) ( Supplementary Figure S2 ), the negative prognostic value of KRAS mutations remains uncertain on the basis of the data in the present study.
However, ISH data showed a trend towards increased Faah (Fig. 11 b, p = 0.1131) and Mgll (Fig. 11 d, p = 0.1419) expression in the TNC neurons (Hedges’ g = 1.2 and 1.1, respectively).
Notably, high IL1RAP expression on tumor cells and stroma combined, was associated with a significantly increased progression-free survival (median: 3.5 vs 1.2 months, p=0.0023) and showed a trend toward extended overall survival (median: 5.0 vs 2.2 months, p=0.1136) with a follow-up of 11.5 months ( figure 7B ).
Patients primarily treated with carboplatin showed a trend towards a prolonged PFS of 7.5 months vs. those receiving cisplatin (3.9 months, p=0.114) (Figure 3A ).
In the population aged < 65 years, patients in the E + dCRT group also showed a trend of better 3-year PFS rate (54.29% [95% CI 36.61–68.98] vs. 33.33% [95% CI 13.65–54.54]; HR for disease progression, 0.58; 95% CI 0.27–1.22; P = 0.114) and 3-year OS rate (80.00% [95% CI 62.58–89.92] vs. 55.56% [95% CI 30.51–74.75]; HR for death, 0.54; 95% CI 0.23–1.23; P = 0.102) compared to those in the dCRT group (Fig. 3 E and F).
The analysis of spirometry parameters showed a trend of increasing serotonin with decreasing FVC (r = −0.397, p = 0.114), ( Figure 3 ).
HMO), except in the MCB group, which showed a trend toward significant difference from the MMO group ( P < 0.114).
Soluble VEGF-R1 showed a trend for decreasing at C2D1 in 16 of 25 patients ( P = 0.114).
However, TNBC patients with high EVI1 showed a trend towards increased pCR rates compared to low group (37.7% vs 27.5%, p = 0.114; odds ratio 1.60 (95%CI 0.90–2.85, p = 0.110) and numerically better DFS (HR = 0.77 [95%CI 0.48–1.23], log-rank p = 0.271) and OS (HR = 0.76 [95% 0.44–1.31], log-rank p = 0.314) without reaching statistical significance.
With respect to the treatment outcome, the OCC group showed a trend of a higher 2-year mortality rate than the NOCC subgroup (43.5% vs. 29.6%, p = 0.115, Table 1 ). 3.2.
SG-based combination therapy showed a trend to improved PFS compared to monotherapy, both in TNBC (14.2 vs 4.6 months, HR = 0.51, p = 0.115) and HoR+HER2− patients (11.3 vs 5.8 months, HR = 0.35, p = 0.159; Supplemental Figure 2 ).
28.2%; p = 0.003), and showed a trend towards reporting less frequently close contact (<2 m distance) with a COVID-19-suspected patient (48.1% vs. 36.0%; p = 0.115). 3.3.
4B ); however, compared with patients with non– CCNE1 -amplified gastric adenocarcinoma, patients with CCNE1 -amplified gastric adenocarcinoma showed a trend toward shorter survival after receiving trastuzumab (HR = 1.694, 95% CI: 0.873–3.289, P = 0.115; Fig. 4C ).
96.1(± 58.2) mg/dL; p = 0.014), and showed a trend toward more severe fibrosis (LSM 15.6(± 19.5) vs. 12.0(± 15.7) kPa; p = 0.115).